DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-10-30
Target enrollment:
Participant gender:
Summary
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant
to systemic therapy progressed following prior therapy. This study will help to understand
what type of side effects may occur with the drug treatment. It will also measure the levels
of drug in the body and assess its anti-cancer activity as monotherapy.